User profiles for "author:Chung-Han Lee"
Chung-Han LeeMSKCC Verified email at mskcc.org Cited by 6840 |
mTOR pathway as a target in tissue hypertrophy
Recent work has shown that the mTOR (mammalian target of rapamycin) pathway is an
integral cell growth regulator. The mTOR pathway involves two functional complexes …
integral cell growth regulator. The mTOR pathway involves two functional complexes …
Update on tumor neoantigens and their utility: why it is good to be different
Antitumor rejection by the immune system is a complex process that is regulated by several
factors. Among these factors are the quality and quantity of mutational events that occur in …
factors. Among these factors are the quality and quantity of mutational events that occur in …
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers,
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …
[PDF][PDF] An integrated metabolic atlas of clear cell renal cell carcinoma
Dysregulated metabolism is a hallmark of cancer, manifested through alterations in
metabolites. We performed metabolomic profiling on 138 matched clear cell renal cell …
metabolites. We performed metabolomic profiling on 138 matched clear cell renal cell …
A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma
Background Vascular endothelial growth factor (VEGF)-targeted therapy is the currently
standard treatment for advanced and metastatic renal cell carcinoma (RCC). Multiple …
standard treatment for advanced and metastatic renal cell carcinoma (RCC). Multiple …
[HTML][HTML] Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid …
PURPOSE Modulation of vascular endothelial growth factor–mediated immune suppression
via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We …
via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We …
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 …
Background Despite advances in the first-line treatment of metastatic renal cell carcinoma
(RCC), there is an unmet need for options to address disease progression during or after …
(RCC), there is an unmet need for options to address disease progression during or after …
[HTML][HTML] Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell
Carcinoma and Genomic Correlates - PMC Back to Top Skip to main content NIH NLM Logo …
Carcinoma and Genomic Correlates - PMC Back to Top Skip to main content NIH NLM Logo …
[HTML][HTML] PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
Abstract Anti-programmed death-1 (anti-PD-1) immunotherapy reinvigorates CD8 T cell
responses in patients with cancer but PD-1 is also expressed by other immune cells …
responses in patients with cancer but PD-1 is also expressed by other immune cells …
Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53
Miscoordination of growth and proliferation with the cellular stress response can lead to
tumorigenesis. Mammalian target of rapamycin (mTOR), a central cell growth controller, is …
tumorigenesis. Mammalian target of rapamycin (mTOR), a central cell growth controller, is …